Last updated: July 1, 2026
Indivior Inc. sued Mylan Technologies Inc. in the U.S. District Court for the District of Maryland under Hatch-Waxman for an ANDA-related generic challenge. The dispute is docketed as 1:15-cv-01016 and centers on patent infringement allegations tied to the challenged Abbreviated New Drug Application and related entitlement to marketing approval. The case’s procedural posture and case-lifecycle milestones (complaint, responsive filings, claim construction, dispositive motions, and final disposition/settlement posture) are not provided in the input, so no complete, accurate litigation summary can be produced.
What is Indivior Inc. v. Mylan Technologies Inc. 1:15-cv-01016 about?
Indivior Inc. v. Mylan Technologies Inc. 1:15-cv-01016 is a federal patent infringement action associated with an ANDA generic entry under 35 U.S.C. § 271(e)(2). These cases typically involve:
- Alleged infringement of one or more listed patents tied to an NDA product.
- Validity challenges (often including § 102/103 obviousness, § 101, and/or § 112) raised by the ANDA filer.
- A litigation schedule with Markman (claim construction) and summary judgment phases.
A litigation summary requires the asserted patents, the specific ANDA product/strength/formulation, and the procedural outcome. Those specifics are not included in the provided information.
What patents were asserted in 1:15-cv-01016?
A complete patent-level summary requires:
- Patent numbers and listed assignee(s)
- Listed NDA reference product
- Claims asserted in the complaint
- Which claims were construed or dropped during litigation
No such data is available in the input.
What ANDA product and FDA submission triggered the litigation?
A complete summary requires:
- The ANDA’s reference listed drug (RLD)
- Dosage form (film, tablet, strip, injection, etc.)
- Strength(s)
- Filing dates and Paragraph IV (or other certification) framework
No such data is available in the input.
What was the procedural timeline for Indivior v. Mylan 1:15-cv-01016?
A litigation timeline must be built from docket events (e.g., complaint filing date, answer, amendments, Markman, summary judgment, trial if any, and final judgment or dismissal with/without prejudice).
The input provides only the case number, not the docket dates or outcomes.
Key docket milestones needed for a timeline
- Complaint filed (date)
- Answer and defenses asserted
- Claim construction order (date)
- Dispositive motion decisions (date)
- Any transfer, consolidation, or related case linkage
- Final judgment, settlement dismissal, or termination (date)
None of these dates are present in the input.
How did the court rule on claim construction, validity, and infringement?
A litigation analysis depends on:
- The construction of disputed terms
- Infringement findings (direct, indirect, induced; literal vs doctrine)
- Validity determinations (anticipation/obviousness, indefiniteness, written description, enablement)
- Any remaining asserted claims after Markman and summary judgment
No decisions or rulings are included in the input.
Was there a Paragraph IV settlement or consent judgment in 1:15-cv-01016?
To evaluate settlement posture, a summary needs:
- Whether parties entered a settlement agreement under 21 U.S.C. § 355(j)
- Whether there was a dismissal with prejudice, consent judgment, or stay pending FDA approval
- The agreed-upon launch date restrictions, market-entry triggers, and any license terms
The input does not include settlement or judgment details.
What is the Orange Book status tied to the asserted Indivior product?
Orange Book status analysis requires:
- Listing of the relevant patents for the RLD (the NDA product)
- Patent expiration dates (including pediatric exclusivity if applicable)
- Exclusivity expiration dates (NCE, 5-year, 3-year, pediatric if tied)
- Whether patents are method-of-use vs composition-of-matter vs formulation/process
No Orange Book listing data is included in the input.
What generic entry risks existed for Mylan based on the litigation?
A generic entry risk assessment requires:
- Which patents survived at the end of litigation
- Any final court rulings invalidating or narrowing asserted claims
- Remaining injunction or order scope
- Whether the ANDA was at risk of final injunction precluding launch
No end-state outcome is available in the input.
How does this case compare with other Indivior v. generic litigation involving Mylan?
A comparison requires:
- Identifying other Indivior v. generic cases by the same generic manufacturer
- Outcomes and whether the same patent families were asserted
- Whether claim construction and validity rulings carried across
No comparative case data is included.
Key Takeaways
- Case identification: Indivior Inc. v. Mylan Technologies Inc., 1:15-cv-01016.
- Required analysis inputs missing: asserted patent numbers, product/RLD, docket timeline, claim construction rulings, validity/infringement findings, and final disposition (judgment vs settlement).
- Result: A complete, accurate litigation summary and analysis cannot be produced from the provided information alone.
FAQs
- What patents are typically asserted in Indivior ANDA Hatch-Waxman cases?
- Do settlements in Indivior generics litigation usually include launch dates or licensing terms?
- How do court claim constructions affect design-around strategies for generics in this space?
- What impact do Orange Book exclusivity and patent expirations have on FDA approval timing after litigation?
- How can docket termination mode (dismissal vs consent judgment) affect future enforcement?
References
- No sources were provided in the input.
